a b s t r a c t CART peptides are peptide neurotransmitters and hormones that are involved in many different physiological responses. While much is known about the peptides regarding their structure, processing and gene regulation, less is known about their postsynaptic actions and receptors. Using 125 I-CART 61-102 as a ligand and unlabeled CART 61-102 or CART 55-102 as displacers, high-affinity specific binding was detected in PC12 cells. Differentiation of the PC12 cells increased specific binding several-fold. The increase in specific binding found after differentiation was inhibited by actinomycin D and cycloheximide, suggesting that the increase in specific binding was dependent on RNA and protein synthesis. CART 1-27, a peptide that has never been shown to elicit responses, did not displace 125 I-CART 61-102 binding, nor did more than 20 other peptides that were examined. Surprisingly, however, PACAP 1-38 and PACAP 6-38 were found to be low-affinity inhibitors of CART binding. CART treatment increased binding of 35 S-GTPgamma-S to PC12 cell membranes. Moreover, CART treatment of intact PC12 cells elicited robust increases in phospho-ERK in a manner that was increased with differentiation, blocked by pertussis toxin and antagonized by PACAP 6-38. These findings extend previous research and suggest that the CART binding site in PC12 cells reflects a G protein-coupled receptor linked with Gi/o, and also demonstrate that PACAP 6-38 may be useful as a CART receptor antagonist.
I-CART 61-102 as a ligand and unlabeled CART 61-102 or CART 55-102 as displacers, high-affinity specific binding was detected in PC12 cells. Differentiation of the PC12 cells increased specific binding several-fold. The increase in specific binding found after differentiation was inhibited by actinomycin D and cycloheximide, suggesting that the increase in specific binding was dependent on RNA and protein synthesis. CART 1-27, a peptide that has never been shown to elicit responses, did not displace 125 I-CART 61-102 binding, nor did more than 20 other peptides that were examined. Surprisingly, however, PACAP 1-38 and PACAP 6-38 were found to be low-affinity inhibitors of CART binding. CART treatment increased binding of 35 S-GTPgamma-S to PC12 cell membranes. Moreover, CART treatment of intact PC12 cells elicited robust increases in phospho-ERK in a manner that was increased with differentiation, blocked by pertussis toxin and antagonized by PACAP 6-38. These findings extend previous research and suggest that the CART binding site in PC12 cells reflects a G protein-coupled receptor linked with Gi/o, and also demonstrate that PACAP 6-38 may be useful as a CART receptor antagonist.
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Introduction
CART peptides are major neuropeptides involved in a variety of functions including the actions of psychostimulants, feeding and body weight, neuroendocrine control, stress, depression and anxiety, and sleep and arousal (Rogge et al., 2008) . In addition to a large number of studies on the behavioral and physiological effects of CART peptides, several key studies of the CART peptide system have been directed at defining the receptor(s) for the peptides. The earliest studies showed effects of the application of CART peptide on intracellular signaling. C-Fos levels were increased in several brain regions after peptide injection (Vrang et al., 1999; Aja et al., 2006; Pirnik et al., 2009) , and adding CART peptide to hippocampal cells in culture resulted in an inhibition of voltage dependant Ca ++ signaling (Yermolaieva et al., 2001 ). The latter effect was blocked by pertussis toxin, suggesting the involvement of Gi/o proteins. Also, icv administration of CART peptide caused an increase in CREB phosphorylation in CRF-containing neuron in the hypothalamic PVN (Sarkar et al., 2004) , and CART peptide induced a phosphorylation of NMDA receptors by PKA and PKC signaling pathways (Chiu et al., 2009 ). Application of CART peptide to cultured AtT20 cells activated ERK signaling which was also reduced by pertussis toxin , and studies of CART-induced signaling in bovine granulosa cells also suggested the involvement of Gi/o proteins (Sen et al., 2007) . Taken together, these studies suggest that CART peptides may exert many effects through a G protein-coupled receptor (GPCR) linked to Gi/o.
CART peptide binding studies have also been undertaken to identify a receptor binding site. Initial attempts aimed at finding specific receptor binding in brain tissue failed, mainly due to the presence of large amounts of nonspecific binding. However, binding studies in cultured cells have been more successful. Following the discovery of CART peptide stimulation of ERK signaling in AtT20 cells, specific binding was found in these same cells that was of high affinity and specific for CART peptides . CART binding has also been found in HepG2 cells and dissociated hypothalamic cells (Keller et al., 2006) , and highaffinity specific binding was found in primary cell cultures of nucleus accumbens neurons . The latter study showed that GTP reduced the binding of CART peptide, but ATP did not, again suggesting a GPCR. Finally, a high-affinity and specific binding of CART peptide was found in PC12 cells Maletinska et al., 2007) ; an interesting aspect of the CART binding in PC12 cells was that it increased after differentiation into a more neuronal phenotype by application of NGF. It is not known, however, if this differentiation-dependent increase in CART binding to PC12 cells correlates with increases in functional CART receptors. Moreover, the pharmacological profile of the CART binding sites in PC12 cells has not been rigorously evaluated.
In this investigation, we explored the correlation between increased CART binding and increased CART-activated signaling in PC12 cells following differentiation. Furthermore, we characterized the pharmacological profile of the CART binding sites in PC12 cells, and surprisingly found that PACAP 6-38 can both displace CART binding and block CART-mediated functional responses. Thus, PACAP 6-38 represents a novel CART receptor antagonist.
Materials and methods

Materials
CART 61-102 was purchased from Bachem (Bubendorf, Switzerland). Other peptides, including: CART 1-27, CART 1-39, all 
Culture of PC12 cells
Rat pheochromocytoma cell line PC12 was purchased from ATCC (Manassas, VA, USA). The cells were grown in RPMI 1640 medium (Invitrogen, Carlsbad, California) supplemented with 10% horse serum, 5% fetal bovine serum, 100 units/ml penicillin, and 100 lg/ml streptomycin. For binding studies, cells were seeded on Polyethylene Imine-coated 24-well plates (Corning, NY, USA). Cells were plated at 1.5 to 2 Â 10 4 in each well and cultured for one day, then the medium was changed to RPMI 1640 supplemented with 1% horse serum, 0.5% fetal bovine serum, 100 units/ml penicillin, and 100 lg/ml streptomycin for one more day. Differentiation of cells was performed by the addition of NGF (50 ng/mL); PACAP (100 nM); or both of NGF and PACAP and confirmed by microscopy. The cell number was determined with Guava ViaCount Reagent (Guava Technologies, Hayward, CA).
Iodination of CART 61-102
CART 61-102 (Bachem, Bubendorf, Switzerland) was iodinated at Tyr62 with 
Binding procedures
125
I-CART 61-102 binding experiments were performed in intact, plated PC12 cells . Plated cells were incubated with 0.03-3 nM 125 I-CART 61-102 in saturation experiments, or with 1 nM 125 I-CART 61-102 and various peptides in competitive binding experiments. Binding was typically carried out in a total volume of 0.15 ml of binding buffer (20 mM HEPES buffer pH 7.4, 118 mM NaCl, 4.7 mM KCl and 5 mM MgCl2, 5.5 mM glucose, 1 mg/ml BSA, and 0.1 mg/ml basic pancreatic trypsin inhibitor) at 4°C for 40 min, then the incubation was continued by transferring the plates to room temperature for 30 min. After incubation, cells were washed twice using cold phosphate buffered saline, and then solubilized in 0.5 mL of 0.25 N NaOH.
Bound radioactivity was determined by c-counting (COBRA II, AUTO-GAMMA, Perkin Elmer, Wellesley, MA, USA). Non-specific binding was determined using 1 lM CART 61-102. As usual, specific binding was determined by subtracting nonspecific from total binding. Experiments were carried out in triplicates at least three times. K d and B max values were calculated by standard procedures using GraphPad Prizm 4 Software (San Diego, CA). K i values were calculated using the Cheng-Prusoff equation (radioligand concentration was 1 nM). In some experiments, Cycloheximide (CHX; 10 lg/ml), Actinomycin D (ActiD; 2 mM) and Cytochalasin D (CytoD; 4 mM) were added to PC12 cells for 30 min, and then treated or not by both NGF and PACAP for 6 h. After that, binding experiments were performed with 5 nM 125 I-CART 61-102. volume of 100 ll. Gpp(NH)p and App(NH)p were pre-incubated with membranes at room temperature for 30 min. The reaction was terminated by adding 4 ml cold phosphate-buffered saline and then immediately centrifuged at 4°C. The surfaces of the pellets were washed twice and radioactivity was measured.
ERK activation and Western blotting
Cells were treated using serum-free medium for at least 16 h, and some samples were treated with PTX (200 ng/m) at the same time. NGF and/or PACAP was not present. CART 55-102 or CART 61-102 (0.3 lM) were added for 5 min and the cells were washed two times with cold PBS and lysed in solubilization buffer (M-PER Mammalian Protein Extraction Reagent (Thermo Scientific, Rockford, IL) containing 2.5 mM sodium pyrophosphate; 1 mM sodium vanadate; 10 lg/mL each of aprotinin and leupeptin; 2 mM phenylmethylsulfonyl fluoride). Total cell lysate for each sample (20 lg) was subjected to SDS-Polyacrylamide gel electrophoresis and electrotransferred to a PVDF membrane (Invitrogen, Carlsbad, CA). After blocking with non-fat dry milk (20 mM Tris-HCl, pH 7.4, containing 150 mM NaCl, 0.1% Tween 20, and 5% (wt./vol.)), the blots were incubated with specific antibodies (anti-p-ERK and anti-ERK) overnight at 4°C. The blots were then incubated with horseradish peroxidase-conjugated secondary antibody. The immunoactivity was visualized through an enhanced chemiluminescence detection system (Amersham Pharmacia Biotech, Piscataway, NJ. The same amount of protein was loaded onto each lane. Densities were determined using Scion Image Software (NIH, Bethesda MD). ''Relative'' p-ERK expression was determined by taking the ratio of p-ERK to ERK band densities and setting that to 1 for controls. Positive control experiments demonstrated that NGF and PACAP 1-38 increased ERK phosphorylation as expected (data not shown).
[ 35 S]-GTPgammaS binding assay
The assay was carried out as described previously (Zhao et al., 1998) . Cells were lysed in 5 mM Tris-HCl, pH 7.5, 5 mM EDTA, 5 mM EGTA at 4°C and the lysate was centrifuged at 30,000g for 10 min. The membrane pellet (containing 5 lg protein) was resuspended and incubated at 30°C for 1 h in 20 mM HEPES, pH 7.4, 10 mM MgCl 2 , 100 mM NaCl, 10 lM GDP, 0.001% saponin and 0.05 nM 
Statistical analysis
Each experiment was repeated a minimum of three times. Statistical analyses were performed using analysis of variance or t tests as needed. Data are presented as means ± SE, and the value of P < 0.05 was considered significant. GraphPad Prism 4 software (San Diego CA) was used for statistical analyses.
Results
Differentiation of PC12 cells by NGF and PACAP, and its effects on specific 125 I-CART 61-102 binding. PC12 cells were incubated with NGF (N), PACAP (P), or both, as described in Section 2. The time course of differentiation was examined and cellular morphology changed over a 3-day time course as expected (not shown). Also, the effect of differentiation by N, P, and N + P on specific CART peptide binding was examined at 1, 2 and 3 days. Without any N or P (no differentiation), CART binding did not change after 3 days. Addition of N alone resulted in a steady increase of binding over the 3-day period. Addition of P alone resulted in an increase in binding at 1 day that did not increase further. Addition of both N and P resulted in the largest increase in binding (Fig. 1a) which was maximal at 1 day and did not change over the 3 days. Binding at earlier time points were also examined after differentiation by both N and P. A significant increase in binding was found after 2 h, and the increase was almost maximal by 6 h (Fig. 1b) . In subsequent studies, both N and P together were used for differentiation unless stated otherwise.
3.1. Saturation of specific binding of 125 I-CART 61-102 to undiffer entiated and differentiated cells PC12 cells were either left undifferentiated or differentiated for 3 days, and binding was carried out as described in Section 2. The 3-day time point was chosen because preliminary experiments showed that maximal binding was stable at that time. K d values for specific binding were determined for both kinds of cells and were not significantly different from each other; the average K d values were 0.61 and 0.51 (nM) as described in Fig. 2 . In agreement with data shown in Fig. 1 , specific binding increased about 4-fold after differentiation.
Specificity of 125 I-CART 61-102 binding
The K d and K i values of CART 62-102, CART 61-102, CART 55-102, and a large number of unrelated peptides were determined in both undifferentiated and differentiated PC12 cells (Table  1) . The K d and K i values of the three CART peptides were not significantly different and were all in the 0.5 nM range. Surprisingly, PACAP 1-38 (P) and PACAP 6-38 inhibited binding, although with low affinity (130-150 nM) (Fig. 3) . The P that was added for differentiation (Fig. 1) was not a factor in the binding experiments because the P was washed from the cells before binding was carried out (see Section 2). All of the more than 20 other peptides examined had K i values greater than 1 lM (Table 1) .
Effects of Gpp(NH)p or App(NH)p on 125 I-CART peptide binding
Because of the evidence in the literature that the CART peptide receptor is a GPCR coupled to Gi/o, at least in some cells, we examined the effects of Gpp(NH)p and App(NH)p on 125 I-CART 61-102 binding to membranes of the differentiated PC12 cells. Membranes were used instead of whole cells to avoid problems with penetration of the reagents into the cells. In these assays, the K d values were 0.68 ± 0.06 nM, and the B max values were 108.5 ± 8.4 fmol/ mg protein. The concentrations of the GTP and ATP analogs were 1, 3, and 10 lM. Binding was more sensitive to Gpp(NH)p than to App(NH)p. Neither analog reduced binding at 1 lM, but Gpp(NH)p reduced binding at 3 lM and 10 lM while App(NH)p did not (Fig. 4) .
Effects of CART 61-102 on 35 S-GTPgammaS binding to PC12 membranes
To test further if the CART binding sites in PC12 cells might correlate with functional CART receptors, the effect of CART 61-102 on the binding of 35 S-GTPgamma-S to PC12 cell membranes was carried out. The binding of 35 S-GTPgamma-S increased significantly upon addition of 10 lM CART 61-102 (Fig. 5) . The binding of 35 S-GTPgamma-S was blocked by 10 lM Gpp(NH)p but not by 10 lM App(NH)p, consistent with the idea that CART peptide interacts with a GPCR in PC12 cells (Fig. 5) .
Effects of CART 61-102 on Phosphorylation of ERK in PC12 cells
We next determined whether CART peptide could increase phospho-ERK levels in PC12 cells as has been found in other cell types . In undifferentiated cells, the effect of peptide addition was small but significant; CART peptide slightly increased phospho-ERK levels, and this was inhibited by pertussis toxin (PTX). In cells treated with N for 3 days, addition of CART 61-102 produced a much more substantial increase in phospho-ERK, which was prevented by PTX. In cells differentiated with both N + P for 3 days, CART 61-102 stimulation yielded an even larger increase in phospho-ERK, which again was inhibited by PTX. PTX alone had no inhibitory effect compared to control (ctrl) (Fig. 6) . CART 55-102 had approximately the same effect as CART 61-102 (data not shown). In accompanying positive control experiments, we confirmed the previously-reported abilities of NGF and PACAP (acute treatments) to stimulate phospho-ERK in both undifferentiated and differentiated PC12 cells (data not shown). These results reveal that CART peptide can activate intracellular signaling through a GPCR coupled to Gi/o in PC12 cells and that CART-activated signaling increases with differentiation in a manner very similar to the increase in CART binding sites observed with differentiation. In order to test if protein synthesis, RNA synthesis, and/or a functional cell cytoskeleton were needed for the increase in CART binding induced by differentiation, various inhibitors were added before and maintained during the differentiation process (see Section 2). In undifferentiated cells, none of the inhibitors had any effects on CART peptide specific binding after 6 h. After 6 h of differentiation with N + P, CART binding increased as expected, and both CHX and ActiD inhibited specific binding, while CytoD was without effect (Fig. 7) . This suggests that transcription and translation are needed for differentiation to produce the increase in binding.
PACAP 6-38 blocks CART peptide activation of p-ERK
Because PACAP 1-38 and PACAP 6-38 were found to inhibit CART binding, and because PACAP 6-38 is a PAC1 receptor antagonist in many systems, we tested if PACAP 6-38 might be an antagonist at the CART peptide receptor as well. Accordingly, we tested if PACAP 6-38 (1 lM) would antagonize the activation of ERK induced by CART 55-102 or CART 61-102 (0.3 lM). Differentiated PC12 cells were prepared and exposed to CART peptides in the absence and presence of PACAP 6-38. Treatment with PACAP 6-38 alone had no effect on phospho-ERK levels. Strikingly, however, the activation of ERK by CART 55-102 (Fig. 8) and CART 61-102 (not shown) was completely blocked by micromolar concentrations of PACAP 6-38. (Fig. 8) . In contrast, PACAP 16-38 had no effect on CART peptide-induced rises in phospho-ERK (data not shown), which is consistent with observations that this peptide also did not displace 125 I-CART 61-102 binding (Table 1) . These data reveal that PACAP 6-38, but not the shorter fragments of PACAP, can antagonize both 
Discussion
In this study, specific binding of 125 I-CART 61-102 was detected in the PC12 cells and increased upon differentiation with NGF, or PACAP or a combination of both NGF and PACAP. It has been established that NGF and PACAP cause differentiation of these cells (Grumolato et al., 2003; Sakai et al., 2004) . The specific binding was saturable with a K d in the subnanomolar range, and was highly specific for active CART peptides. The specific binding and CART signaling in the PC12 cells is more robust than in other cells Vicentic et al., 2006) in that between 50% and 80% of the total binding is specific in differentiated PC12 cells, but is much less in other cell types. This is a useful and practical technical advantage. These findings confirm and build on those of Maletinska et al. (2007) and Maixnerova et al. (2007) in PC12 cells, as we extend studies on the properties of CART binding and also assess CART-stimulated signaling in these cells.
We found that CART peptides increased the binding of 35 SGTPgamma-S in differentiated PC12 cells in a manner that was sensitive to Gpp(NH)p but not App(NH)p, indicating that 125 I-CART 61-102 interacts with a G protein-coupled receptor in PC12 cells. CART 1-27 >1000 >1000 CART 1-39 >1000 >1000 CART 55-76 >1000 >1000 NPY >1000 >1000 Angiotensin II >1000 >1000 CRF >1000 >1000 GLP-1 >1000 >1000 GLP-2 >1000 >1000 Vasopressin >1000 >1000 Neurotensin >1000 >1000 VIP >1000 >1000 GABA >1000 >1000 Galanin >1000 >1000 Ghrelin >1000 >1000 Orexin A >1000 >1000 Orexin B >1000 >1000 Complement 5a >1000 >1000
Specificity of 125 I-CART 61-102 binding to PC12 cells. Experiments were carried out as described in Section 2. Data are mean ± SEM nM (n = 3-5). The blank spaces in the table indicate that those experiments were not done. See text for additional details. The binding was sensitive to Gpp(NH)p; 3 and 10 lM reduced CART binding whereas the same concentrations of App(NH)p had no effect. Radioligand concentration was 1 nM. Data are mean ± SEM, (n = 3-6). Asterisks indicate P < 0.01. Analysis was by one way ANOVA with Tukey's post hoc test. See Text for additional details. Also, we tested if CART peptides would increase phospho-ERK levels in the differentiated PC12 cells. Interestingly, we found that the ability of CART to stimulate ERK activation increased with cell differentiation, similar to the increase in CART binding sites observed upon differentiation of the PC12 cells. Moreover, the increase in phospho-ERK levels was blocked by pertussis toxin, which provides additional evidence that the CART receptor couples to G proteins. We found that CART binding to PC12 cells was specific and could not be displaced by inactive fragments of CART. These data are consistent with results from studies on other cell types. In AtT20 cells, for example, radiolabeled CART peptide binding could not be inhibited by a variety of peptides and small molecules at concentrations up to 1 lM . Moreover, nonradioactive CART 55-102 did not block radioligand ligand binding to any of 30 different peptide and additional receptors (Vicentic et al., 2006) . Earlier studies on PC12 cells showed that various fragments of active CART peptides without the three disulfide bridges were only very weak inhibitors of CART peptide binding , see also Dylag et al., 2006) . Taken together, these findings indicate that the CART peptide receptor is very specific for active CART peptides. There have been reports of some smaller CART fragments, such as 62-76 and 85-102, having some functional activity in vivo , but the effects are modest and require very high peptide concentrations, as we have shown with CART 62-76 (Lambert et al., 1998) . Surprisingly, we found that PACAP 1-38 and PACAP 6-38 were low-affinity inhibitors of CART peptide binding in PC12 cells. More than 20 other peptides were also examined, including other PACAP fragments, but only PACAP 1-38 and PACAP 6-38 were found to possess the ability to displace CART binding at sub-micromolar levels. Maxadilan and maxadilan antagonist, peptides known to interact with PACAP receptors (Moro et al., 1999; Tatsuno et al., 2001; Pereira et al., 2002; Reddy et al., 2008) did not block CART peptide binding. Thus, given the low affinity of PACAP 1-38 and PACAP 6-38 for displacing CART binding, and the lack of maxadilan displacement, it seems very likely that the CART binding sites in PC12 cells do not represent PACAP receptors. Moreover, earlier studies have shown that PACAP 6-38 is a weaker displacer of PA-CAP binding than PACAP 1-38 whereas the opposite was found in our studies for displacement of CART peptide binding Gourlet et al., 1995) . Because PACAP 6-38 is an antagonist of PACAP 1-38 at PAC1 receptors, at least in certain tissues Vandermeers et al., 1992; Tornoe et al., 1997; Leyton et al., 1998) we tested if PACAP 6-38 might act as a CART receptor antagonist. Interestingly, PACAP 6-38 did antagonize the ability of CART to stimulate ERK activation. These data are significant because there are no currently accepted antagonists for the CART receptor, and this has been a major hindrance to many studies on CART actions. Although PACAP 6-38 exhibits relatively low affinity for the CART receptor, and even though it is not specific for the CART peptide receptor, it could be used as a lead compound in a search for more potent analogs.
In summary, these studies confirm the presence of saturable, specific binding of 125 I-CART 61-102 in PC12 cells, which increased upon differentiation of the cells. We have also significantly expanded upon previous studies in PC12 cells by providing a detailed pharmacological characterization of the CART binding sites and demonstrating that the increase in binding sites upon differentiation correlates with a striking increase in CART-activated signaling. We found that CART peptides enhanced 35 S-GTPgammaS binding and increased phospho-ERK levels in a manner that was blocked by pertussis toxin. These data are consistent with the idea that the CART binding sites in PC12 cells represent GPCRs coupled to Gi/o. Importantly, the present studies identified PACAP 6-38 as a low-affinity CART receptor antagonist. These studies provide novel information about the properties of the CART receptor and set the stage for the potential targeting of this receptor by therapeutics.
